DE602007006813D1 - Medikament zur verbesserung der kognitiven funktion und neuroprotektion - Google Patents
Medikament zur verbesserung der kognitiven funktion und neuroprotektionInfo
- Publication number
- DE602007006813D1 DE602007006813D1 DE602007006813T DE602007006813T DE602007006813D1 DE 602007006813 D1 DE602007006813 D1 DE 602007006813D1 DE 602007006813 T DE602007006813 T DE 602007006813T DE 602007006813 T DE602007006813 T DE 602007006813T DE 602007006813 D1 DE602007006813 D1 DE 602007006813D1
- Authority
- DE
- Germany
- Prior art keywords
- memory
- cognitive function
- pyridazinone
- benz
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 230000003920 cognitive function Effects 0.000 title abstract 2
- 208000000044 Amnesia Diseases 0.000 abstract 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 abstract 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000031091 Amnestic disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000006986 amnesia Effects 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 abstract 1
- 231100000863 loss of memory Toxicity 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 230000006993 memory improvement Effects 0.000 abstract 1
- 230000003340 mental effect Effects 0.000 abstract 1
- 230000016273 neuron death Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0600555A HUP0600555A3 (en) | 2006-07-03 | 2006-07-03 | Use of 4-chloro-5-{2-[4-(6-fluoro-1,2-benz[d]izoxazol-3-yl)piperidin-1-yl]ethylamino}2-methyl-3(2h)-piridazinon for the production of pharmaceutical compositions for influencing cognitive functions and causing neuroprotective effect |
PCT/HU2007/000059 WO2008004013A2 (en) | 2006-07-03 | 2007-07-03 | Medicament for the enhancement of cognitive function and neuroprotection |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602007006813D1 true DE602007006813D1 (de) | 2010-07-08 |
Family
ID=89986887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602007006813T Active DE602007006813D1 (de) | 2006-07-03 | 2007-07-03 | Medikament zur verbesserung der kognitiven funktion und neuroprotektion |
Country Status (26)
Country | Link |
---|---|
US (1) | US8318743B2 (de) |
EP (1) | EP2049113B8 (de) |
JP (1) | JP5174018B2 (de) |
KR (1) | KR101465415B1 (de) |
CN (1) | CN101516373B (de) |
AT (1) | ATE468854T1 (de) |
AU (1) | AU2007270910B2 (de) |
BR (1) | BRPI0713395A2 (de) |
CA (1) | CA2656549C (de) |
CY (1) | CY1110741T1 (de) |
DE (1) | DE602007006813D1 (de) |
DK (1) | DK2049113T3 (de) |
EA (1) | EA016142B1 (de) |
HK (1) | HK1131032A1 (de) |
HR (1) | HRP20100465T1 (de) |
HU (1) | HUP0600555A3 (de) |
IL (1) | IL196315A (de) |
MA (1) | MA30951B1 (de) |
MX (1) | MX2009000243A (de) |
NZ (1) | NZ574596A (de) |
PL (1) | PL2049113T3 (de) |
PT (1) | PT2049113E (de) |
RS (1) | RS51429B (de) |
SI (1) | SI2049113T1 (de) |
WO (1) | WO2008004013A2 (de) |
ZA (1) | ZA200900507B (de) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP9602763A3 (en) * | 1996-10-09 | 1999-05-28 | Egyt Gyogyszervegyeszeti Gyar | 3-phenyl isoxazole derivatives, process for producing them and pharmaceutical compositions containing the same |
AU7547100A (en) * | 1999-09-09 | 2001-04-10 | Egis Gyogyszergyar Rt. | Alkylpiperidi nylbenzo [d] isoxazole derivatives having psychotropic activity, pharmaceutical compositions containing the same, and a process for the preparation of the active ingredient |
HU225955B1 (en) * | 2001-07-26 | 2008-01-28 | Egis Gyogyszergyar Nyilvanosan | Novel 2h-pyridazin-3-one derivatives, process for their preparation, their use and pharmaceutical compositions containing them |
US20030024849A1 (en) * | 2001-07-26 | 2003-02-06 | Nielsen Jacob Sturich | Package for blister pack strips |
HU227118B1 (en) * | 2001-11-13 | 2010-07-28 | Egis Gyogyszergyar Nyilvanosan | Process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzizoxazol-3-yl)-1-piperidinyl]-ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one |
HU227255B1 (en) * | 2002-04-26 | 2010-12-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Novel piperidine-alkyl-amino-pyridazine derivatives, pharmaceutical compositions containing the same and process for the preparation of the active ingredient |
-
2006
- 2006-07-03 HU HU0600555A patent/HUP0600555A3/hu unknown
-
2007
- 2007-07-03 KR KR1020097002214A patent/KR101465415B1/ko not_active IP Right Cessation
- 2007-07-03 DK DK07766491.0T patent/DK2049113T3/da active
- 2007-07-03 EA EA200900088A patent/EA016142B1/ru not_active IP Right Cessation
- 2007-07-03 RS RSP-2010/0375A patent/RS51429B/en unknown
- 2007-07-03 CN CN2007800306551A patent/CN101516373B/zh not_active Expired - Fee Related
- 2007-07-03 SI SI200730327T patent/SI2049113T1/sl unknown
- 2007-07-03 NZ NZ574596A patent/NZ574596A/xx not_active IP Right Cessation
- 2007-07-03 BR BRPI0713395-2A patent/BRPI0713395A2/pt not_active IP Right Cessation
- 2007-07-03 AU AU2007270910A patent/AU2007270910B2/en not_active Ceased
- 2007-07-03 WO PCT/HU2007/000059 patent/WO2008004013A2/en active Application Filing
- 2007-07-03 CA CA2656549A patent/CA2656549C/en not_active Expired - Fee Related
- 2007-07-03 JP JP2009517450A patent/JP5174018B2/ja not_active Expired - Fee Related
- 2007-07-03 PT PT07766491T patent/PT2049113E/pt unknown
- 2007-07-03 DE DE602007006813T patent/DE602007006813D1/de active Active
- 2007-07-03 ZA ZA200900507A patent/ZA200900507B/xx unknown
- 2007-07-03 AT AT07766491T patent/ATE468854T1/de active
- 2007-07-03 US US12/307,385 patent/US8318743B2/en not_active Expired - Fee Related
- 2007-07-03 EP EP07766491A patent/EP2049113B8/de active Active
- 2007-07-03 MX MX2009000243A patent/MX2009000243A/es active IP Right Grant
- 2007-07-03 PL PL07766491T patent/PL2049113T3/pl unknown
-
2009
- 2009-01-01 IL IL196315A patent/IL196315A/en not_active IP Right Cessation
- 2009-01-27 MA MA31589A patent/MA30951B1/fr unknown
- 2009-09-11 HK HK09108358.0A patent/HK1131032A1/xx not_active IP Right Cessation
-
2010
- 2010-08-18 CY CY20101100766T patent/CY1110741T1/el unknown
- 2010-08-23 HR HR20100465T patent/HRP20100465T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
CA2641473A1 (en) | Condensed imidazole derivatives as aldosterone synthase inhibitors | |
NZ592961A (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
JP2008513516A5 (de) | ||
NO20073853L (no) | Faste, oralt applikerbare farmasoytiske administreringsformer inneholdende nvaroksaban med modifisert frigivelse | |
MX336774B (es) | Moduladores alostericos positivos de receptores m1 de la quinolina amida. | |
MA33593B1 (fr) | Composés hétérocycliques et leurs utilisations | |
NO20091596L (no) | Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer | |
WO2008002621A3 (en) | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | |
UY30426A1 (es) | Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones. | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
HRP20120144T1 (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity | |
PL1940844T3 (pl) | Związki i kompozycje jako inhibitory kinazy białkowej | |
EA201071006A1 (ru) | Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности | |
JPWO2007097403A1 (ja) | 消化管潰瘍治療又は予防薬 | |
NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
ATE547417T1 (de) | Dihydropyrimidinverbindungen und ihre verwendungen bei der herstellung von medikamenten zur behandlung und prävention antiviraler krankheiten | |
HK1146049A1 (en) | Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1 | |
NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
ATE357453T1 (de) | Comt-inhibitoren | |
DE602007006813D1 (de) | Medikament zur verbesserung der kognitiven funktion und neuroprotektion | |
JP2013542976A (ja) | ニトロベンゾチアゾール誘導体および結核治療のためのこれらの使用 | |
WO2009069680A1 (ja) | 消化管間質腫瘍(gist)を処置するための医薬組成物、ならびに消化管間質腫瘍を患う患者の予後を予測するためのキットおよび方法 | |
WO2008020256A3 (en) | 3,4-dihydrobenzo[1,2,3]thiadiazine-1,1-dioxide derivatives, process for preparation thereof, medicaments containing said derivatives and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: EGIS GYOGYSZERGYAR NYRT, BUDAPEST, HU |
|
8364 | No opposition during term of opposition | ||
R082 | Change of representative |
Ref document number: 2049113 Country of ref document: EP Representative=s name: STOLMAR & PARTNER, DE |